Havens Advisors LLC acquired a new position in shares of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 103,760 shares of the company’s stock, valued at approximately $2,171,000. Vitae Pharmaceuticals makes up 1.7% of Havens Advisors LLC’s portfolio, making the stock its 17th largest position. Havens Advisors LLC owned approximately 0.36% of Vitae Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of VTAE. Schwab Charles Investment Management Inc. raised its stake in shares of Vitae Pharmaceuticals by 143.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 80,791 shares of the company’s stock worth $872,000 after buying an additional 47,602 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Vitae Pharmaceuticals by 64.7% in the second quarter. Alps Advisors Inc. now owns 40,515 shares of the company’s stock worth $437,000 after buying an additional 15,920 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Vitae Pharmaceuticals by 69.0% in the second quarter. JPMorgan Chase & Co. now owns 319,100 shares of the company’s stock worth $3,443,000 after buying an additional 130,300 shares during the last quarter. Oxford Asset Management raised its stake in shares of Vitae Pharmaceuticals by 221.5% in the second quarter. Oxford Asset Management now owns 314,326 shares of the company’s stock worth $3,392,000 after buying an additional 216,544 shares during the last quarter. Finally, California State Teachers Retirement System raised its stake in shares of Vitae Pharmaceuticals by 93.4% in the second quarter. California State Teachers Retirement System now owns 55,134 shares of the company’s stock worth $595,000 after buying an additional 26,633 shares during the last quarter. 72.58% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)

Shares of Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) remained flat at $21.00 during midday trading on Monday. The company’s 50 day moving average is $0.00 and its 200 day moving average is $0.00. Vitae Pharmaceuticals Inc. has a 52 week low of $4.08 and a 52 week high of $21.03.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2016/11/28/havens-advisors-llc-acquires-new-stake-in-vitae-pharmaceuticals-inc-vtae.html.

A number of analysts have issued reports on VTAE shares. Piper Jaffray Cos. lowered Vitae Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, September 20th. Wells Fargo & Co. lowered Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Sunday, September 11th. JMP Securities downgraded Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. Stifel Nicolaus downgraded Vitae Pharmaceuticals from a “buy” rating to a “hold” rating and set a $21.00 price objective on the stock. in a report on Wednesday, September 14th. Finally, Wedbush downgraded Vitae Pharmaceuticals from an “outperform” rating to a “neutral” rating and raised their price objective for the stock from $21.00 to $23.00 in a report on Wednesday, September 14th. Seven equities research analysts have rated the stock with a hold rating, The stock has an average rating of “Hold” and an average target price of $19.05.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 1,025,000 shares of Vitae Pharmaceuticals stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $20.85, for a total transaction of $21,371,250.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey S. Hatfield sold 50,000 shares of Vitae Pharmaceuticals stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $20.81, for a total value of $1,040,500.00. Following the transaction, the chief executive officer now owns 244,996 shares in the company, valued at approximately $5,098,366.76. The disclosure for this sale can be found here. Insiders own 14.80% of the company’s stock.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

5 Day Chart for NASDAQ:VTAE

Receive News & Stock Ratings for Vitae Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.